Oncolytic adenoviruses (Ad) represent a promising therapeutic platform for the treatment of cancer. Despite their reliable safety and ease of handling, the recognized oncolytic Ad immune responses, biodistribution, spreads and efficacy of viral replication, compared with non-replicating adenoviruses, in vivo, have not been well understood. The present study establishes a novel permissive mouse immunocompetent orthotopic colon carcinoma model focusing on non-replicating Adv-TKs, a well-established adjuvant treatment in cancer and comparing its antitumor efficacy and safety profile with those of the two newly synthesized oncolytic Ad vectors, M7 and M8, formed by the insertion of a fragment of HSV-TK cDNA into the deleted 6.7 K/gp19 K or ADP in the E3 region to the E1A CR2-deleted Ad5 vectors. Systemic administration in the permissive immunocompetent orthotopic colon carcinoma mouse model, which could better predict the clinical results of Ad-based treatment by combining the characteristics that fully mimic the clinical orthotopic carcinogenesis and permissive Ad replication, show M7 and M8, especially M8, to have more powerful antitumoral efficacy and similar safety profiles relative to the Adv-TK. This promises a significant advance in the field of Ad cancer therapy and will perhaps provide the impetus to design new preclinical M7 and M8 viruses in the future.
INTRODUCTION
Adenovirus (Ad) vectors have been one of the most commonly used vectors in preclinical and clinical trials because they were clinically evaluated and proven safe, but there are still some major problems needing further resolution. First, immune responses against Ad vectors pose a possible concern for the efficacious outcome of treatment. However, hitherto most published animal tumor model efficacy data with adenoviruses have come from immunodeficient mouse-human tumor xenograft models. [1] [2] [3] [4] Viral agents like Ad have complex biologics that include interactions with host cell machinery and immune response effectors, 5, 6 therefore, the impact of the immune response should be certainly quite complex. Efficacy might be reduced because of viral clearance, 7 conversely, it might increase efficacy because of induction of specific (e.g., tumor-specific cytotoxic T lymphocytes) and nonspecific (e.g., tumor necrosis factor) immunity. 8 Little work has been carried out to address this issue because of a lack of immunocompetent and permissive animal models.
Second, despite the rapid placement of systematic administration of oncolytic adenoviruses in human clinical trials and its demonstrated safety, direct intratumoral injection, which severely limits the potential action of adenoviruses in vivo, is now still the major administration route of Ad therapy in clinical use. [9] [10] [11] [12] Could oncolytic adenoviruses reach, spread and effectively replicate in the local primary tumor and other infected organs after systematic administration?
Third, although murine low permissive cancer cell lines, cotton rats and Syrian hamsters were discovered recently as permissive immunocompetent animal models for investigating oncolytic Ad vectors, [13] [14] [15] subcutaneous tumor models were mostly chosen in the published studies. [16] [17] [18] [19] However, subcutaneous tumor model failed to fully mimic the characteristics of the orthotopic carcinogenesis in clinic. Therefore, it was necessary to develop orthotopic tumor models in immunocompetent animal to better predict the clinical results.
Last, Ad5 vectors, known, respectively, as the first generation, second generation and oncolytic adenovirus, have been studied extensively in preclinical and clinical trials. However, few systemic comparisons of these Ad vectors that have reflected the vertical history of Ad-based cancer gene therapy strategies have hitherto been undertaken.
We have previously reported two types of oncolytic adenoviral vector systems. The first was generated by replacing the 6.7 K/ gp19 K region with a fragment of antisense complementary DNA (cDNA), specific for a target gene in an E1A CR2 region-deleted adenoviral mutant called Adv5/dE1A. 20, 21 The second was generated by replacing the Ad death protein (ADP) gene in the E3 region. 22 Previous studies have demonstrated that in these systems, transgenes can be efficiently expressed by native E3 promoters at a level superior to that driven by the human cytomegalovirus early major promoters. More importantly, expression of the transgenes is dependent on active viral DNA replication and mimics the expression kinetics of the E3 genes replaced by the transgenes. adjuvant treatments in cancer. Herpes simplex virus thymidine kinase (HSV-TK) converts a benign substance (prodrug) ganciclovir (GCV) into toxic nucleotide analogues, which are incorporated into DNA during cell division, terminate DNA replication and lead to cancer cell death. Moreover, TK transduction effectively eradicates cancer cells via a bystander effect of gene therapy. 23, 24 In this study, we chose Adv-TK and compared its efficacy and safety with those of the two newly synthesized oncolytic Ad vectors encoding the HSV-TK gene, both of which share a 27-bp deletion in the E1A region of wild-type (wt) Ad5 that endows them with oncolytic potentialities, namely M7 and M8. In the M7 virus, HSV-TK cDNA replaced the 6.7 K/gp19 K of E3 region, whereas in the M8 virus, HSV-TK cDNA replaced the ADP of E3 region. Low permissive murine colon carcinoma cell line CMT-93 was used to establish an immunocompetent orthotopic colon carcinoma murine model, and further compared in vivo for antitumoral effects and safety profiles of the M7 and M8, respectively, with Adv-TK, a first generation of replication-deficient Ad vector constructed in-house, in this model.
RESULTS

Construction and characterization of M7 and M8
The M7 and M8 mutant adenoviruses ( Figure 1a ) were designed and engineered employing two genetic manipulations from wt-Ad5 genome. First, a 27-bp sequence corresponding to wt-Ad5 bases 920-946 was deleted to generate Ad5/dE1A. This deletion induced the expression of a mutant E1A protein lacking the CR2 domain necessary for pRb binding. Second, the E3 transcription unit of the Ad5/dE1A genome, corresponding to wt-Ad5 bases 28530-29360, known to encode the E3 6.7 K and gp19 K proteins, was excised and replaced with a 1131-bp fragment of the HSV-TK gene cDNA with a ClaI restriction site introduced at each end to generate the M7 virus. Similarly, the M8 virus was generated by excising wtAd5 bases 29477-29714, known to encode the ADP protein, and replaced with HSV-TK cDNA. The genomic structures of M7 and M8 were verified by ClaI restriction endonuclease and further confirmed by PCR (Figures 1b and c) and sequencing (data not shown).
To monitor the replication ability of the three adenoviral mutants in murine cancer CMT-93 cells, real-time PCR was performed to assess mRNA levels of viral fiber, a late structural viral gene whose expression is dependent on active viral replication. Fiber transcripts were nearly undetectable in Adv-TKinfected CMT-93 cells, demonstrating their lack of viral replication. In M7-infected CMT-93 cells, moderate levels of the fiber transcript were detected, which were similar to those observed in wt-Ad5-infected cells. And M8-infected CMT-93 cells expressed the highest levels of the fiber transcript among these groups after 48 h infection, suggesting powerful viral replication capacity (Figure 1d) . In viral production assays, CMT-93 cells infected with 10 multiplicity of infection (MOI) M7 yielded viral titers similar to that of wt-Ad5 after 72 h of infection, and the highest viral titers were yielded in M8-infected CMT-93 cells (Figure 1e M7 and M8 viruses displayed superior in vitro antitumoral effects in CMT-93 cells when compared with Adv-TK To better assess the effect of the three adenoviral mutants in vitro, we optimized the dosages of GCV. An in vitro GCV sensitivity assay was performed on CMT-93 cells. This assay demonstrated that the highest non-toxic GCV treatment dose was 100 μg ml − 1 (Figure 2a ). Subsequently, we assessed the effects of the three viral mutants on CMT-93 cells across a wide dose range (MOI of 0.2-50) in the presence of GCV (100 μg ml − 1 ). When the antitumor activity was compared, the data at low doses (2 MOI) of M7 and M8 showed both had antitumor activity superior to that of Adv-TK in combination with 100 μg ml − 1 GCV, while M8 showed the most potent effect of all the mutants. This difference, however, disappeared at high doses (50 MOI) (Figure 2b ). In contrast, in normal cells (MCF-10A and human umbilical cord endothelial cells (HUVEC)), the three viral mutants showed no effect at an MOI of 50 (Figure 2c and d ), but at a high MOI of 500, transfect efficacy was about 70% in HUVEC and 30% in MCF-10A cells, only M8 did not affect the proliferation. M7 and Adv-TK inhibited proliferation by less than 15% and 25%, respectively (Figures 2c and d) . Similar results were obtained using flow cytometry to detect apoptosis in CMT-93, HUVEC and MCF-10A cells (Figures 2e, f and g ).
Orthotopic colon carcinoma mice model exhibited extensive growth of local tumors We first established the orthotopic colon carcinoma murine model. Orthotopic implantation of the murine colon cell line CMT-93 reached a 100% take rate for local tumor growths ( Figures  3a and b) . However, local tumor growths were slow before tumor volumes reached around 100 mm 3 (about 4 weeks after implantation), the biggest tumor volume observed was smaller than that of the orthotopic human gastric carcinoma murine model reported previously, 25 the tumor volume of 603.20 ± 55.80 mm 3 being reached at 10 weeks (Figure 3c ). No obvious metastasis was found during the whole observation period. It was worthy to note that the mice were emaciated with the growth of local tumors relative to normal mice ( Figure 3d ), with the model mice beginning to die as early as 4 weeks after implantation because of intestinal obstruction caused by orthotopic tumors and serious malnutrition (Figure 3e ), which together mimic the clinical characteristics of human colon cancer. In subsequent experiments, the model mice were employed to study the therapeutic outcome and toxicity of three adenoviral mutants after systemic administration.
We further evaluated the antitumoral activity of the three Ad mutants in the orthotopic colon carcinoma mice model. 1.25 × 10 10 vp of Ad5/dE1A, Adv-TK, M7 or M8 which were administered intravenously (i.v.) in combination with GCV against CMT-93 orthotopic colon cancers in mice 21 days after transplantation when local tumor volumes reached around 60 mm 3 ( Figure 4a ). M7 and M8 shows suppressed tumor growth to an extent superior to that achieved by administration of Adv-TK ( Figure 4b) . Moreover, the effect of M8 was superior to that of M7, suggesting that M7 and M8, and especially M8, suppressed tumor growth more potently than Adv-TK in immune-competent mouse model. While all mice (12 of 12) treated with GCV alone died before day 100 after transplant, survival of the mice treated with M7 and M8 was superior to that of the mice treated with Adv-TK, and the highest survival rate was achieved with M8 treatment (Figure 4c ), indicating that suppressing tumor growth prolonged the survival time. Furthermore, no mice showed serious abnormalities in behavior, their furs, neurological response, breathing and defecation were observed to be no different among each group.
M7 and M8 could replicate in orthotopic colon carcinoma mice model, induce the second peak of TK expression and enduringly stimulate immune system Our previous studies demonstrated that i.v. administration of adenoviral mutants could give rise to efficient infection and replication in murine xerographic models of orthotopic human gastric cancer, 25 but whether i.v. administration of adenoviral mutants could give rise to similar effect on immune-competent murine orthotopic tumor models was unknown. To address this, mice were euthanized at the indicated time after injection and local tumors were harvested for further analysis. Real-time PCR was performed to detect the fiber by using the template of DNA extracted from the tumor, which could indicate the Ad amount in the orthotopic tumor. As shown in Figure 5a , fiber DNA was detected easily in local tumor sites after i.v. injection of adenovirus, indicating that i.v. administration of adenoviral mutants could give rise to efficient infection in immunecompetent murine tumors. By day 7 after injection, the second peak was seen in Ad5/dE1A-, M7-and M8-injected tumors but not in Adv-TK-injected tumors, with the most abundant in M8-infected mice even at day 14 post injection. Similar results were obtained in detecting fiber transcript expressions representing active replication by using the template of RNA extracted from the tumor (Figure 5b ). Data presented here were found to be consistent with the results from TK mRNA and protein expression curves, which showed strongest viral particles and TK protein expressions readily detected in M8-infected mice (Figures 5c-f) .
Inflammatory cytokines interleukin (IL)-2, tumor necrosis factor (TNF)-β and interferon (IFN)-γ were produced by T cells, and have been shown to play a major role in the regulation of both cell-mediated immunity and humoral T-cell-dependent immune responses; therefore, to investigate the local immune status induced by the adenoviral mutants, mice were euthanized at the indicated time after injection and local tumors were harvested and the expression of IL-2, TNF-β and IFN-γ in the local tumor was detected by real-time PCR. Injection of the adenoviral mutants induced a sharp increase of IFN-γ and TNF-β, and reached the first peak at day 4 (Figures 5g and h ), but had no effect on the expression of IL-2 (Figure 5i ). Although the expression of IFN-γ and TNF-β in the Adv-TK-injected group dropped to almost undetectable levels after day 7, the M7-and M8-injected group reached the second peak at day 14. Surprisingly, the expression of IFN-γ and TNF-β in the M8-injected group lasted at a related high levels by 28 days post injection.
The biodistribution of the adenoviral mutants in the orthotopic colon carcinoma mice model To determine the biodistribution and dynamics of adenoviral mutants after i.v. administration, the mice were killed at the indicated time points, with their livers, kidneys, spleens and lungs being harvested for real-time PCR and immunohistochemistry (IHC). As shown in Figure 6 , injection of the adenoviral mutants gave rise to efficient spread to the liver, kidney, spleen and lung at day 1, thereafter dropping to comparatively low levels. The dynamics of the adenoviral mutants showed no obvious difference among the four groups and different organs (Figures 6a  and d) . The tropism of Ad to liver was analyzed by the dynamics of the adenoviral mutants in the liver by IHC. At day 1 after injection, M8 was detected both in liver cells and liver blood sinus. M8 was only detected in the liver blood sinus by day 4, and nearly disappeared by day 14 post injection (Figures 6e and f) . Similar results were obtained from M7-injected groups. In Adv-TK-injected groups, there was nearly no Adv-TK detected by day 7 after injection (data were not shown).
DISCUSSION
Oncolytic Ad represents a rapidly growing novel option for cancer therapy. A major limitation, however, has been the lack of an ideal immune-competent model to evaluate both the antitumor efficacy and safety. Most published animal tumor model efficacious data with oncolytic adenoviruses have come from immunodeficient murine-human tumor xerographic models, which fail to fully assess the safety of replicating vectors as well as to measure the effect of the immune system on the vector or the tumor. [5] [6] [7] To our knowledge, the present study is the first report to compare the gene expression, replication, oncolysis, biodistribution, immunity and antitumoral activities of the first generation of replication-deficient Ad Adv-TK to those of oncolytic adenoviruses M7 and M8 after systemic delivery by using a new permissive orthotopic tumor model in immunocompetent animals.
There are several advantages of the orthotopic colon carcinoma murine model. Firstly, the model was constructed based on an immunocompetent mouse, allowing assessment of the antitumor effects of replicating vectors as well as the effect of the immune system on the vector or the tumor mentioned above. Secondly, to construct this model, a murine colon carcinoma cell line CMT-93 was used to permit minimal Ad replication. In our study, we confirmed that replication-selective oncolytic adenoviruses M7 and M8 could replicate in and lyse CMT-93 cells both in vitro and in vivo. Thirdly, compared with the previously reported subcutaneous tumor models, this orthotopic tumor model could more accurately mimic the clinic characteristics of colon cancer such as the extended local invasive growth, malnutrition and emaciation, intestinal obstruction, and so on. However, there are also some defects observed in this model, such as lower Ad replication ability in this model vis-à-vis that in human tumors, as second peak in Figures 5a-c is 10-100-fold lower than the first peak after Ad-TK injection, indicating only modest replicative capacity not leading to efficient vector spread. Therefore, the mouse is not a good model system to answer questions related to the safety of Ad as a therapeutic tool in humans. However, the purpose of this study was to compare the immune responses, biodistribution, spreads and therapeutic effects in oncolytic adenoviruses with those nonreplicating adenoviruses. In this sense, this permissive mouse immunocompetent orthotopic colon carcinoma model, which combined the characteristics of immunocompetence and bearing tumor, could answer this question. Second, during the whole study period, no visible metastasis was observed; this could be possibly related to the properties of the CMT-93 cells, which is not consistent with clinical carcinogenesis of colon cancer.
Ad5 E3 region is an ideal site for developing the transgene delivery capacity of the virus because the E3 region is nonessential for viral replication in vitro. [26] [27] [28] Furthermore, the transcriptional complexity here results in E3 proteins being expressed at varying times and levels over the course of the viral infection. Therefore, we modified two different regions of E3 and replaced them with TK genes to generate M7 and M8 adenoviral mutants. The 6.7 K/gp19 K region, which was replaced in the M7 virus, serves in the evasion of detection and eradication by Ad-specific cytotoxic T lymphocytes. 6, [29] [30] [31] Cytotoxic T lymphocyte evasion by tumor cells is also well documented and can take many forms. Therefore, the deletion of 6.7 K per gp19 K in the M7 virus cannot be expected to affect viral DNA replication and lysis of infected cells. [32] [33] [34] [35] [36] Actually, E3 6.7 K per gp19 K region deletion led to increased replication and antitumoral efficacy, with the similar virus quantity, gene expression and antitumoral activity with M8 by day 7 post injection. A similar therapeutic effect of E3 gp19 Kdeleted Ad has been reported in immunocompetent mice bearing CMT-93 subcutaneous tumors. 37 This evidence, which was different from the results here, showed less gene expression, viral replication and oncolysis than M8 in mouse orthotopic gastric carcinoma xerographic models (data not published). Although the exact mechanism by which E3 6.7 K/gp19 K region deletion results in improved intratumoral gene expression and/or replication is not clear at this time, we think we can estimate from the data that prolonged TNF and IFN-γ expression are induced by Ad in the M7-injected tumors. These cytokines had potent antivascular and cell-cycle inhibitory properties.
Unlike other E3 genes, the ADP gene replaced in the M8 virus is expressed almost exclusively during the late phase of the viral infection and is responsible for the efficient lysis and release of progeny virus. [38] [39] [40] Consequently, a cell infected with an ADPdeleted virus can live longer and serve as a 'factory' for therapeutic protein synthesis, using both viral-replication-derived genomic amplification and extended cell viability and protein synthesis to better produce the therapeutic transgene. Therefore, we detected increased expressions of TK, enhanced viral replication and prolonged survival time in M8-injected orthotopic tumors, and the second peak of IFN-γ and TNF-β was seen at a related high level by 28 days post injection in the M8-injected group.
Concerns about safety in immunized hosts limit the clinical utility of therapeutic Ad vectors; this is especially true for oncolytic adenoviruses. Compared with the Gelsinger case, where about 5 × 10 11 kg − 1 dosage was calculated by the infusion of a total of 38 trillion virus particles into the blood, here in our study, the C57BL/ 6 mice were injected almost the same dosage, which was about 6.25 × 10 11 kg − 1 (if 20 g per mice) as in the Gelsinger case. Data presented here did not show serious side effects in mice compared with the Gelsinger case, partially because of modest replicative capacity and insensitivity of mice to Ad not leading to death.
Another important finding of this study was that the distribution and metabolism of the replication-deficient Ad Adv-TK and replication-competent Ad M7 or M8 did not show much difference after systemic administration. We tested the expression of fiber transcripts by hybridization in situ, which represented the active replication in non-tumor tissues and got the negative result. Because the mice are non-permissive for adenovirus, we did some in vitro experiment to see the difference of virus replication in human normal cells, such as HUVECs and non-transformed mammary epithelial cell lines (MCF-10A), with M7 and M8, which showed low transfect efficacy and an enlarged therapeutic window between tumor cells and normal cells, therefore partly reflecting the safety of M7 and M8. Although the three virus mutants could give efficient infections to the liver, kidney, lungs and spleen, the immune system eradicated them soon enough. Only the replication-competent Ad M7 or M8 could give rise to second peaks and enduringly stimulated the immune system in immune-competent orthotopic colon carcinoma murine models, which could increase the antitumor efficacy without inducing dangerous risks.
Overall, this study introduced a new permissive immunocompetent orthotopic carcinoma animal model to evaluate the efficiency and safety of replication-deficient Ad Adv-TK and the oncolytic adenoviruses M7 and M8 after systemic delivery. This would appear to be a significant advance in the field of Ad cancer therapy and the results presented here will provide the impetus to design the preclinical development of the M7 and M8 viruses in the future.
MATERIALS AND METHODS
Cells and viruses
CMT-93(murine colon cancer cell lines), HEK293(human embryonic kidney cell lines) and MCF-10A (non-transformed mammary epithelial cell lines) were purchased from the American Type Culture Collection (Manassas, VA, USA); HUVECs (human umbilical cord endothelial cells) were purchased from Lonza (Allendale, NJ, USA) and cultured following the manufacturer's instructions. All Adv5 mutants used in the present studies were constructed in in-house laboratories following protocols detailed elsewhere. Ad5/dE1A with deletion of amino acids 121-129 in E1A CR2 was previously constructed. 41 The replication-deficient Ad vector Adv-TK, containing HSV-TK gene under control of a Rous sarcoma virus long terminal repeat promoter in the region of the excised E1 adenoviral genes was constructed in this laboratory as previously described. 42 Wt-Ad5 was obtained from American Type Culture Collection. M7 and M8 were derived from Ad5/dE1A through replacement of the gp19 K and ADP open reading frame in the E3 region by a fragment of HSV-TK cDNA, respectively. The viral mutant was constructed by homologous recombination as described previously. 20 Verification of M7 and M8 M7 or M8-infected HEK293 cells were cultured for 3 days. Viral DNA was isolated and digested with ClaI for electrophoresis separation or for PCR verification. Primers used for PCR were as follows: TK P1 5′-ATCGATACCAT GGCTTCGTACCCCG-3′, P2 5′-ATCGATTCAGTTAGCCTCCCCCAT-3′.
Western blot
Preparation of protein samples and western blot were carried out as described previously. 22 Antibodies to TK and β-Actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
In vitro cytotoxicity assay
Seventy percent confluent CMT-93 cells were infected with Ad5/dE1A, wt-Ad5, Adv-TK, M7 or M8 for 90 min at a MOI of 10 and then transferred to complete culture mediums. For cytotoxicity assays, the culture plates were stained with 0.1% crystal violet solution (Sigma Chemical Co., St Louis, MO, USA) 96 h after infection.
Real-time PCR
Quantitative PCR was performed using the SYBR Green Real-Time PCR method. Each sample was tested in triplicate, and relative gene expression was analyzed using the 2 − ΔΔCT method, and results were expressed as fold induction compared with the untreated group. PCR was performed with a 5′ sense primer (5′-ACTATATGGACAACGTCAACCCATT-3′) and a 3′ antisense primer (5′-ACCTTCTGAGGCACCTGGATGT-3′) for fiber of Adv5. To amplify 18S RNA internal control, a 5′ sense primer (5′-AGT CCC TG C CCT TTG ACA CA-3′) and a 3′ antisense primer (5′-GAT CCG AGG G CC TCA CTA AAC-3′) were used. To amplify TK, a 5′ sense primer (5′-CAG CAA GAA GCC ACG GAA GT-3′) and a 3′ antisense primer (5′-AG C ACC CGC CAG TAA GTC AT-3′) were used.
MTT assay
CMT-93 cells were seeded at a density of 5 × 10 3 cells per well in 96-well plates. After 24 h, cells were infected with Ad5/dE1A, Adv-TK, M7 and M8 in 50 μl of culture medium per well at various MOIs, and 50 μl of complete medium containing 100 μg ml − 1 of GCV was co-administered. MTT (Promega, Madison, WI, USA) assay was carried out at indicated times as described previously. 22 Apoptosis assay CMT-93 cells were infected with various viral mutants at MOI of 1 or 10, 100 μg ml − 1 of GCV was co-administered, and at specified times, cells were collected, stained and analyzed using a FACSort Flow Cytometer (Becton Dickinson, San Jose, CA, USA) as described previously. 20 Immunohistochemistry IHC was performed on continuous formalin-fixed, paraffin-embedded tissue sections to detect adenoviral particles as described previously. 25 Mouse tumor models All animal protocols were approved by the Institutional Animal Care and Use Committee of Tongji Medical College. C57BL/6 mice were purchased from the Animal Experimental Center of Slaccas (Shanghai, China), aged 4-6 weeks, weighing 16-18 g, with male and female each occupying one half. At first, 1 × 10 6 CMT-93 cells were injected subcutaneously in the flanks of C57BL/6 mice and allowed tumor to grow to 7-8 mm; the mice were killed, the mouse colon cancer tumors propagated in C57BL/6 mice were resected aseptically and then cut into several small pieces about 1-2 mm in diameter in Hanks' balanced salt solution. At the same time, healthy mice were anesthetized, their rectal walls were carefully exposed, and a part of the serosal membrane in the initial sigmoid colonic wall was mechanically injured using scissors. A piece of tumor tissue was implanted into the injured site. The growth of the orthotopic tumor and the survival time of the orthotopic colon cancer xenografts were recorded. Treatment was initiated when tumors had grown to 4-5 mm, total of 1.25 × 10 10 vp of virus was injected for five consecutive days (5-6 mice per group). GCV (60 mg kg − 1 d − 1 ) in 100 μl of saline was injected intraperitoneally once daily for 14 consecutive days. The mice were killed at indicated times after treatment or when they had become moribund. Tumors, spleens, livers, lungs, kidneys and so on were collected at necropsy and processed for virus quantification and histopathologic evaluation. A parallel experiment was carried out for assessing the survival rate of the orthotopic colon cancer xenografts in each group.
Measurement of cell cytokines
Mice were killed at the indicated time after injection and any orthotopic tumors were harvested. Levels of IFN-γ, TNF-a and IL-2 in tumor cells were evaluated using quantitative PCR. A 5′ sense primer (5′-CACCGTCAGCCGA TTTGC-3′) and a 3′ antisense primer (5′-TTGACGGCAGAGAGGAGGTT-3′) were used for mouse TNF-β, a 5′ sense primer (5′-CTGCTGATGGGAGGAGA TGTC-3′) and a 3′ antisense primer (5′-TGCTGTCTGGCCTGCTGTTA-3′) were used for mouse IFN-γ, and a 5′ sense primer (5′-CCCAAGCAGGCCACAGAA-3′) and a 3′ antisense primer (5′-CGCAGAGGTCCAAGTTCATCT-3′) were used for mouse IL-2.
Statistical analysis
Statistical values are presented as mean ± s.d. The significance of differences between groups was assessed by the two-tailed Student's t-test. To compare tumor size between difference groups in mouse experiments, we performed a one-way ANOVA followed by NewmanKeuls. Statistical significance was defined as Po0.05. Survival was analyzed by the Kaplan-Meier method and differences were analyzed by a log-rank test. All P values were two-sided. SPSS version 17.0 software was used for statistical analysis.
